Anticandidal Therapeutics

Developments of antifungal agents have declined as compared to other antibiotics that have displayed a potent development with time. There is an urgent need for both prophylactic and therapeutic treatments worldwide to control the severity of infections caused by Candida. Anticandidal Therapeutics: Discovery and Development provides the readers with a compiled knowledge of the fungal human infection Candida and the development of anticandidal drugs. Anticandidal Therapeutics helps researchers form the basis for the discovery and development of novel anticandidal therapies. In 14 chapters this book provides collective information on anticandidal agents and their discovery and development with respect to major drug transporter families, different stages of anticandidal agent development, recent trends and progress in antifungal translational research, clinical studies status of anticandidal therapeutic agents, and drug repurposing for development of novel anticandidal agents. Highlights the mechanistic actions of some therapeutic agents against Candida Focuses on anticandidal agents rather than general antifungal agents Discusses the stage of development of new antifungal drugs, the repositioning of drugs, and how this could help in treatment

Anticandidal Agents provides the latest information on candida drug resistance and its remedial implications. In this compilation, users will find a comprehensive view on overcoming resistance in anticandidal drugs, along with information on novel molecules. Candida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines. Lately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics. Presents a complete understanding of candida resistance to help in the development of therapeutic expansion and novel drugs Provides thorough information on candida drug resistance and its remedial implications Covers crucial mechanisms of resistance that will help develop strategies for overcoming the hindrance in current therapeutics

This new edition of Antifungal Therapy aims at providing concise, practical, need-to-know information for busy physicians dealing with fungal infections, such as infectious disease physicians, transplant surgeons, dermatologists, and intensivists, as well as basic scientists and pharmaceutical company researchers interested in the state of antifungal therapy. It provides a comprehensive, up-to-date overview of the pertinent issues pertaining to antifungal treatment including the basics of clinical mycology, management insights for various infections, evidence-based treatment recommendations, and helpful tables summarizing currently available pharmacokinetics data. Key Features • Features useful information on administration, dosage and pharmacology of antifungal drugs that can be difficult to use in clinical practice • Contains common Clinical Questions & Answers to highlight frequently encountered patient issues • Covers clinical mycology essentials in addition to antifungal treatment to create a well-rounded reference • Presents illustrations and clinical photos in full color to elucidate the concepts • Provides detailed evidence of treatment recommendations

A concise one-stop-practical reference for the various physicians dealing with fungal infections, Antifungal Therapy appeals to infectious disease physicians, transplant surgeons, dermatologists, and intensivists, as well as basic scientists and pharmaceutical company researchers interested in the state of antifungal therapy. This book provides a c

Fungal infections have taken a new spectrum due to the increased incidence of multi-drug resistant fungal pathogens. Freedom of choice for drugs to treat fungal infections is also narrow because of lesser probability of discovering drugs that would bypass affecting human cells and target fungal cells producing fewer side effects in patients. An approach has gained prominence in research is to look for bioactive antifungal compounds from natural to synthetic sources. It is necessary to discover new classes of antifungals to control the recent emergence of multi-drug resistant fungal infections. This book proposed a details top to bottom outline of antifungal compounds derived naturally or synthetically. The details of their modifications or synthetic analogues have been described, helpful to understand the structure-activity relationship which leads to new compound development in antifungal chemotherapy. Each chapter begins with a comprehensive, top-bottom in-depth discussion of antifungal agents with updated bibliographic references. This compendium will serve as a companion not only for Scientists, Researchers, and Professors, Medical Practitioners but also a valuable reference text for the university students.

This book is an up-to-date practical guide to the treatment of both common and unusual bacterial, fungal, and protozoal skin infections. Antibiotics and other treatment options for common skin diseases such as acne, rosacea, erysipelas, and impetigo are extensively discussed, and a thorough update is provided on therapies for fungal infections in the nails, hair, and skin. Current treatments for skin symptoms associated with sexually transmitted diseases are also explored in detail. A range of mycobacterial infections are discussed, and a further chapter considers the treatment of protozoal infections, including leishmaniasis, which are often unfamiliar to practitioners in the Western world. This handy book, with its helpful graphics and clear lists of symptoms, treatments, and practical tips, will be an ideal quick reference for the busy practitioner.

Candida, which was discovered more than a century ago as a causative organism of oral thrush, is now thought to potentially infect almost every tissue of the human body. Although we still do not have a safe anti-candida drug, the growing pace of progess of research on Candida albicans holds promise that a breakthrough is imminent. Though many monographs and articles on candida and candidoses have appeared in recent years, they mostly cover the clinical aspects. This particular text, however, explains the more basic features of candida including the molecular genetics, molecular biology and immunology of the cell wall, the molecular basis of morphogenesis and the structure and function of the plasma membrane. The role of anti-candida drugs and their mechanism of action are also discussed.

Fungal pathogens pose an on-going and serious threat for poikilotherms and homeotherms, and can cause a broad spectrum of diseases ranging from innocuous to life-threatening. In addition, long-term exposure to some mycotoxigenic moulds can lead to mycotoxicoses in human and animals. Given the expanding population of immune compromised hosts, the list of fungal opportunists grows longer every year. Moreover, antifungal resistance, drug-related toxicity and our limited arsenal of antifungals have exacerbated the situation. To address these problems, strategies such as the identification of novel targets, use of the structure-activity relationship in rational drug design, development of new formulations, modification of existing antifungals to combat resistance, and bioavailability enhancement are called for. For the reader’s convenience, this book has been divided into three sections. The first six chapters of Section I provide a timely review of mycoses, from endemic to cosmopolitan and from generalized to specific, while both chapters of Section II focus on risks associated with mycotoxins. In closing, the two chapters of Section III describe potential antifungal leads and drug candidates based on phytochemicals and coumarin scaffold.